This will be a multi-center, multi-national, investigator-initiated and lead, retrospective analysis assessing the safety and the clinical use of covered stents for the treatment of dysfunctional vascular access.
This will be a multi-center, multi-national, investigator initiated and lead retrospective analysis assessing the safety and the clinical use of covered stents for the treatment of the dysfunctional vascular access. There are no limitations on the type of covered stent use, the reason, or the length of the treatment area. The only limitations are the one owed to covered stent diameter and that patients included in the study should be treated for only one treatment area. The criteria for inclusion, the outcome measures and the variables that should be recorded are listed below. There is also no limitation if data has been previously published in another study, however data as part of an ongoing study, or of a study in press cannot be submitted. Due to previous experience from similar studies it is known that it will be difficult to have data available for all re-interventions. Thus, study will focus on primary patency and safety. Nevertheless, centers should provide data regarding circuit survival (thrombosis, abandonment, surgical revision, patient's death). Terms and definitions of outcome measures are provided below. Study's final follow-up date is March 31st, 2021. Patient should have a minimum follow-up of 6 months to be included in the study at that timepoint, unless circuit is no longer in use (thrombosis, abandonment, surgical revision, patient's death). If a scientific committee's approval is needed for the data collection, it is the center's responsibility to acquire it. If this is waived due to the nature of the study, this should also be stated. A large number of data will be recorded so hopefully, a lot of meaningful evidence will come up from this effort. As seen below, situations out of those allowed in the instructions for use for covered stents are included (ruptures, pseudoaneurysms, cannulation zone placement etc).
Study Type
OBSERVATIONAL
Enrollment
1,000
Covered stent placement for the treatment of dysfunctional vascular access of hemodialysis patients
Effectiveness: Clinically assessed intervention-free period of the treated segment
A dialysis access circuit with no need for clinically driven treatment area repeat intervention for symptom recurrence and angiographic verification of the presence of stenosis at the treatment area.
Time frame: 6 months
Safety: Procedural Complications
Procedure-related Minor Complications No therapy, no consequence Nominal therapy, no consequence; includes overnight admission for observation only Procedure-related Major Complications Require therapy, minor hospitalization (\<48 hours). Require major therapy, unplanned increase in level of care, Prolonged hospitalization (\>48 hours). Permanent adverse sequelae Death
Time frame: 30 days
Access Circuit Primary Patency
The interval of patency after an endovascular intervention until any repeat intervention of the access circuit.
Time frame: 12 months
Postintervention assisted primary patency
The interval of patency after the endovascular intervention until dialysis circuit thrombosis or a surgical intervention of the access circuit. Endovascular interventions in a previously treated lesion and a new arterial or venous outflow stenosis or occlusion (excluding access thrombosis) are compatible with assisted primary patency. Assisted primary patency ends with percutaneous thrombolysis/thrombectomy or surgical circuit thrombectomy
Time frame: 12 months
Anatomic success
Defined as the resumption of normal hemodialysis for a minimum of at least 1 session following percutaneous intervention.
Time frame: 12 months
Clinically assessed intervention-free period of the treated segment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
A dialysis access circuit with no need for clinically driven treatment area repeat intervention for symptom recurrence and angiographic verification of the presence of stenosis at the treatment area.
Time frame: 12 months